What's new? Log in Free sign up

Astellas Pharma (ALPMF)

Company Profile

Company profile

Ticker

ALPMF

Exchange

Website

www.astellas.com

CEO

Mr. Naoki Okamura BSc

Location

SEC CIK

IRS number

132971791

ALPMF stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Third party tender offer statement (amended)

Third party tender offer statement (amended)

Third party tender offer statement (amended)

Third party tender offer statement

Information about tender offer

Information about tender offer

Information about tender offer

Third party tender offer statement (amended)

Third party tender offer statement (amended)

Third party tender offer statement (amended)

Transcripts

Earnings call transcript

Latest ownership filings

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

CYTOKINETICS INC

OSI PHARMACEUTICALS INC

News

From Benzinga Pro

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns.

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise

Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.